PubMed Journals Articles About "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS" RSS

14:35 EST 14th December 2018 | BioPortfolio

Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS articles that have been published worldwide.

More Information about "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS" on BioPortfolio

We have published hundreds of Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS news stories on BioPortfolio along with dozens of Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS Clinical Trials and PubMed Articles about Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS Companies in our database. You can also find out about relevant Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS Drugs and Medications on this site too.

Showing "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS" PubMed Articles 1–25 of 30,000+

Anti-Inflammatory Therapy for Atherosclerosis:Interpreting Divergent Results from the CANTOS and CIRT Clinical Trials.

Over the past 18 months, two multi-national clinical trials specifically designed to test the inflammation hypothesis of atherothrombosis have been presented. First, the 10,061 patient Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) proved that specific targeting of interleukin-1β can significantly reduce cardiovascular event rates in the absence of lipid or blood pressure lowering. In CANTOS, canakinumab given at doses of either 150 or 300 mg SC once every three months lowered the inflamm...

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).

Canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduces rates of recurrent cardiovascular events without lowering lipids. It is uncertain, however, to what extent these beneficial cardiovascular outcomes are mediated through interleukin-6 (IL-6) signalling, an issue with substantial pathophysiologic consequences and therapeutic implications.

Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke.

The CANTOS trial underscored the efficacy of selective antibody-based interleukin (IL)-1β inhibition with Canakinumab in secondary prevention of cardiovascular events. Despite the success of the trial, incidence of stroke was not reduced likely due to the low number of events and the relatively young age of patients enrolled. Given the established role of IL-1β in stroke, we tested the efficacy of the murine Canakinumab-equivalent antibody in a mouse model of ischaemic stroke. To mimic the clinical scenar...

Dietary intake of anthocyanins and risk of cardiovascular disease: A systematic review and meta-analysis of prospective cohort studies.

Accumulating evidence suggests flavonoid intake is associated with reduced risk of non-communicable diseases. We aimed to systematically determine and quantify the potential association between dietary anthocyanin intake and risk of cardiovascular diseases (CVD). A systematic literature search of studies reporting anthocyanin intake and risk of fatal or nonfatal CVD was performed using SCOPUS, MEDLINE, CINAHL and Cochrane Library. The relative risk (RR) or hazard ratio (HR) of highest category of anthocyani...

Diabetic and Elder Patients Experience Superior Cardiovascular Benefits After Gastric Bypass Induced Weight Loss.

Obesity and obesity related co-morbidities are well-recognized risks for cardiovascular (CV) disease and mortality. Weight loss improves CV risk factors and the efficacy of bariatric surgery in decreasing CV mortality is now well-established. Our aim was to assess CV risk progression and occurrence of CV events in a cohort of patients that underwent Roux-en-Y gastric bypass (RYGB) for obesity treatment in a single academic public center. Ten year CV risk was estimated using the Framingham Equation at basel...

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated.

Therapeutic agents targeting cardiometabolic risk for preventing and treating atherosclerotic cardiovascular diseases.

Targeting atherogenic lipoprotein levels with statins remains the current cornerstone of atherosclerotic cardiovascular disease (ACVD) management. In patients at high ACVD risk who cannot achieve the desired low-density lipoprotein (LDL) cholesterol target, the addition of compounds such as ezetimibe and proprotein subtilisin/kexin type-9 (PCSK9) inhibitors incrementally lowers cardiovascular risk. New glucose-lowering drugs such as glucacon-like peptide-1 receptor (GLP1R) agonists and sodium-glucose co-tra...

Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors.

Chronic kidney disease (CKD) is a major risk factor for cardiovascular disease but is often associated with other risks such as diabetes and hypertension and can be both a cause and an effect of cardiovascular disease. Although epidemiologic data of an independent association of reduced glomerular filtration rate with cardiovascular risk are strong, causative mechanisms are unclear. Living kidney donors provide a useful model for assessing the "pure" effects of reduced kidney function on the cardiovascular ...

Microbiota-Host Crosstalk: A Bridge Between Cardiovascular Risk Factors, Diet, and Cardiovascular Disease.

Cardiovascular disease is the leading cause of death and is also a major cause of disability worldwide. Indeed, even in well-treated patients for hypertension or dyslipidemia, there is still a high cardiovascular risk called residual risk. It is of utmost importance to identify the pathway leading from risk factors to cardiovascular disease to further improve stroke and myocardial infarction prevention. In this review, we presented some of experimental and epidemiological evidences suggesting that microbiot...

The utility of long-term blood pressure variability for cardiovascular risk prediction in primary care.

Blood pressure (BP) is a long-established risk factor for cardiovascular disease (CVD). SBP is used in all widely used cardiovascular risk scores for clinical decision-making. Recently, within-person BP variability has been shown to be a major predictor of CVD. We investigated whether cardiovascular risk scores could be improved by incorporating BP variability with standard risk factors.

Dementia risk assessment and risk reduction using cardiovascular risk factors.

Given the poor efficacy of disease modifying treatments and evidence that Alzheimer's Disease (AD) pathophysiology begins in middle-age, efforts to reduce the substantial disease burden have shifted towards preventative intervention in midlife. Up to a third of all AD (the commonest cause of dementia) is attributable to modifiable cardiovascular risk factors. A tool for predicting risk of future dementia using only cardiovascular risk factors has been validated and the effect of lifestyle modification on fu...

Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis.

Cardiovascular disease (CVD) continues to be a leading cause of death worldwide with atherosclerosis being the major underlying pathology. The interplay between lipids and immune cells is believed to be a driving force in the chronic inflammation of the arterial wall during atherogenesis. Atherosclerosis is initiated as lipid particles accumulate and become trapped in vessel walls. The subsequent immune response, involving both adaptive and immune cells, progresses plaque development, which may be exacerbat...

Effects of Primary Cardiovascular Prevention on Vascular Risk in Older Adults.

Primary cardiovascular prevention through simultaneously targeting multiple risk factors may be even more effective than single risk factor modification in older adults. The effects of multicomponent cardiovascular prevention on cardiovascular risk are explored.

Dosage Considerations for Canakinumab in Children with Periodic Fever Syndromes.

Periodic fever syndromes are a group of rare diseases with a highly variable onset, yet limited treatment options are available for children at an early age. Canakinumab has been approved to treat patients with cryopyrin-associated periodic syndrome (CAPS), a periodic fever syndrome, and systemic juvenile systemic arthritis (SJIA), with age cutoffs of 4 years and 2 years, respectively. In 2016, FDA approved canakinumab, without an age restriction, for the treatment of three conditions of periodic fever synd...

Sex-Specific Associations of Risk-Based Alcohol Drinking Level with Cardiovascular Risk Factors and the 10-Year Cardiovascular Disease Risk Scores.

To assess sex-specific associations between risk-based alcohol drinking levels and the 10-year cardiovascular disease (CVD) risk scores and cardiovascular (CV) risk factors.

Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?

Appropriate algorithms for the prediction of cardiovascular risk are strongly suggested in clinical practice, although still controversial. In type 2 diabetes mellitus (T2DM), the beneficial effect of phosphodiesterase (PDE)-5 inhibitors is demonstrated on endothelial function but not on the estimation of cardiovascular risk.

Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: a meta-analysis of cardiovascular outcomes trials.

To show long-term cardiovascular safety of the GLP-1 receptor agonists for diabetes patients with cardiovascular risk.

The Art of Cardiovascular Risk Assessment.

The authors would like to submit two corrections on the recently published manuscript, Art of Cardiovascular Risk Assessment. In section 4, the original sentence states: "However, the SCCT does not recommend use of a CAC score in low-risk patients with an ASCVD risk of < 10%." We would like to correct this to "Furthermore, the SCCT recommends consideration of a CAC score in those with a risk score of 5-20% and selectively in those with lower predicted risk who have a family history of premature ASCVD or oth...

Comparison Between Non-High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol to Estimate Cardiovascular Risk Using a Multivariate Model.

Although studies exist comparing low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (HDL-C) in the development of cardiovascular disease (CVD), most have limitations in the mathematical models used to evaluate their prognostic power adjusted for the other risk factors (cardiovascular risk).

Investigation of the cardiovascular risk profile in a south Brazilian city: surveys from 2012 to 2016.

The aim of this study was to investigate the cardiovascular risk profile of the participants recruited from stroke awareness campaigns in Santa Maria RS, Brazil, from 2012 to 2016, using the simplified version of the Framingham Risk Score (FRS). Questionnaires were used to evaluate 1,061 participants from 20 to 74 years old. Data on cardiovascular risk factors were obtained. The prevalence of risk factors and mean FRS for men and women were estimated. The FRS for women was 11.8% (moderate risk) and 24.7% fo...

Associations of miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms with Ischemic Stroke in the Northern Chinese Han Population.

BACKGROUND Recently, miR-146a C>G, miR- 149 T>C, miR-196a2 T>C and miR-499 A>G polymorphisms have been associated with susceptibility to many diseases, including ischemic stroke (IS). However, results have been reported inconsistency in IS, especially in the Chinese population. This study aimed to investigate the polymorphisms of the 4 miRNAs and IS risk in the Chinese population. MATERIAL AND METHODS We used a case-control study to explore these associations in 396 patients with IS and 378 healthy controls...

Evaluation of community pharmacists' preparedness for the provision of cardiovascular disease risk assessment and management services: A study with simulated patients in Qatar.

Individuals who suffer from major cardiovascular events every year have one or more risk factors. Cardiovascular disease (CVD) risk assessment is an important strategy for the early identification of modifiable risk factors and their management. There is substantial evidence that shifting the focus from treatment to primary prevention reduces the burden of CVD.

Sex-specific risk factors for cardiovascular disease in women-making cardiovascular disease real.

Sex-specific differences in pathophysiology, prevalence, and impact of cardiovascular disease (CVD) risk factors may explain the high cardiovascular mortality rates in women.

Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences.

Practice guidelines recommend that clinicians engage patients in treatment decisions and explain atherosclerotic cardiovascular disease (ASCVD) risk but do not describe how to communicate this risk most effectively.

Patient cardiovascular risk self-management: results from a randomized trial of motivational interviewing delivered by practice nurses.

To enhance cardiovascular risk management and patients' self-management, a tailored programme to improve cardiovascular risk management was tested in a randomized trial. The presented study concerned secondary analysis.

Quick Search